Literature DB >> 26644313

A Patient with CTLA-4 Haploinsufficiency Presenting Gastric Cancer.

Seiichi Hayakawa1, Satoshi Okada2, Miyuki Tsumura1, Sonoko Sakata1, Yoshitaka Ueno3, Kohsuke Imai4, Tomohiro Morio4, Osamu Ohara5, Kazuaki Chayama3, Masao Kobayashi1.   

Abstract

Cytotoxic T-lymphocyte-antigen 4 (CTLA-4) is an essential negative regulator expressed on regulatory T cells (Tregs) and activated T cells. Germline heterozygous mutations in CTLA4 lead to haploinsufficiency of CTLA-4, resulting in the development of an autosomal dominant immune dysregulation syndrome with incomplete penetrance. We report here a Japanese patient with this disorder who has a novel heterozygous single nucleotide insertion, 76_77insT (p. L28SfsX40), in the CTLA4 gene. Peripheral blood mononuclear cells from the patient showed decreased frequency of CTLA-4(high) cells in CD4(+)FOXP3(+) cells following CD3/CD28 stimulation. The patient experienced hypogammaglobulinemia, recurrent pneumonia, esophageal candidiasis, cytomegalovirus-positive chronic gastritis, chronic and severe diarrhea, and type 1 diabetes mellitus. Moreover, the patient developed multifocal gastric cancer, histologically poorly and well-differentiated adenocarcinomas, associated with chronic atrophic gastritis and intestinal metaplasia. Previously, 23 symptomatic cases with heterozygous CTLA4 mutations have been reported. Including the case presented here, 3 of the 24 cases (12.5%) developed gastric cancer. Notably, 2 of 3 patients presented similarly multifocal adenocarcinomas associated with atrophic gastritis and intestinal metaplasia. Predisposition to gastric cancer has been also reported in CVID patients. These clinical observations suggest that gastric cancer is a disease commonly associated with autosomal dominant immune dysregulation syndrome due to CTLA4 mutation.

Entities:  

Keywords:  Autosomal dominant immune dysregulation syndrome; CTLA-4; FOXP3; Gastric cancer; Regulatory T cells

Mesh:

Substances:

Year:  2015        PMID: 26644313     DOI: 10.1007/s10875-015-0221-x

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  8 in total

1.  Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4.

Authors:  Sebastian Zeissig; Britt-Sabina Petersen; Michal Tomczak; Espen Melum; Emilie Huc-Claustre; Stephanie K Dougan; Jon K Laerdahl; Björn Stade; Michael Forster; Stefan Schreiber; Dascha Weir; Alan M Leichtner; Andre Franke; Richard S Blumberg
Journal:  Gut       Date:  2014-11-03       Impact factor: 23.059

2.  Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.

Authors:  Tibor Bakacs; Jitendra N Mehrishi
Journal:  Immunobiology       Date:  2014-12-06       Impact factor: 3.144

3.  Common variable immunodeficiency classification by quantifying T-cell receptor and immunoglobulin κ-deleting recombination excision circles.

Authors:  Chikako Kamae; Noriko Nakagawa; Hiroki Sato; Kenichi Honma; Noriko Mitsuiki; Osamu Ohara; Hirokazu Kanegane; Srdjan Pasic; Qiang Pan-Hammarström; Menno C van Zelm; Tomohiro Morio; Kohsuke Imai; Shigeaki Nonoyama
Journal:  J Allergy Clin Immunol       Date:  2012-12-28       Impact factor: 10.793

4.  Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study.

Authors:  L Mellemkjaer; L Hammarstrom; V Andersen; J Yuen; C Heilmann; T Barington; J Bjorkander; J H Olsen
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

Review 5.  Risk factors in gastric cancer.

Authors:  D Compare; A Rocco; G Nardone
Journal:  Eur Rev Med Pharmacol Sci       Date:  2010-04       Impact factor: 3.507

Review 6.  Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme.

Authors:  F Dhalla; S P da Silva; M Lucas; S Travis; H Chapel
Journal:  Clin Exp Immunol       Date:  2011-04-06       Impact factor: 4.330

7.  Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.

Authors:  Hye Sun Kuehn; Weiming Ouyang; Bernice Lo; Elissa K Deenick; Julie E Niemela; Danielle T Avery; Jean-Nicolas Schickel; Dat Q Tran; Jennifer Stoddard; Yu Zhang; David M Frucht; Bogdan Dumitriu; Phillip Scheinberg; Les R Folio; Cathleen A Frein; Susan Price; Christopher Koh; Theo Heller; Christine M Seroogy; Anna Huttenlocher; V Koneti Rao; Helen C Su; David Kleiner; Luigi D Notarangelo; Yajesh Rampertaap; Kenneth N Olivier; Joshua McElwee; Jason Hughes; Stefania Pittaluga; Joao B Oliveira; Eric Meffre; Thomas A Fleisher; Steven M Holland; Michael J Lenardo; Stuart G Tangye; Gulbu Uzel
Journal:  Science       Date:  2014-09-11       Impact factor: 47.728

8.  Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.

Authors:  Desirée Schubert; Claudia Bode; Rupert Kenefeck; Tie Zheng Hou; Lucy S K Walker; David M Sansom; Bodo Grimbacher; James B Wing; Alan Kennedy; Alla Bulashevska; Britt-Sabina Petersen; Alejandro A Schäffer; Björn A Grüning; Susanne Unger; Natalie Frede; Ulrich Baumann; Torsten Witte; Reinhold E Schmidt; Gregor Dueckers; Tim Niehues; Suranjith Seneviratne; Maria Kanariou; Carsten Speckmann; Stephan Ehl; Anne Rensing-Ehl; Klaus Warnatz; Mirzokhid Rakhmanov; Robert Thimme; Peter Hasselblatt; Florian Emmerich; Toni Cathomen; Rolf Backofen; Paul Fisch; Maximilian Seidl; Annette May; Annette Schmitt-Graeff; Shinji Ikemizu; Ulrich Salzer; Andre Franke; Shimon Sakaguchi
Journal:  Nat Med       Date:  2014-10-20       Impact factor: 53.440

  8 in total
  16 in total

Review 1.  The Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies.

Authors:  Dror S Shouval; Matthew Kowalik; Scott B Snapper
Journal:  J Clin Immunol       Date:  2018-06-29       Impact factor: 8.317

2.  Neurological Involvement in Childhood Evans Syndrome.

Authors:  Thomas Pincez; Bénédicte Neven; Hubert Ducou Le Pointe; Pascale Varlet; Helder Fernandes; Albane Gareton; Guy Leverger; Thierry Leblanc; Hervé Chambost; Gérard Michel; Marlène Pasquet; Frédéric Millot; Olivier Hermine; Alexis Mathian; Marie Hully; Hélène Zephir; Mohamed Hamidou; Jean-Marc Durand; Yves Perel; Judith Landman-Parker; Fréderic Rieux-Laucat; Nathalie Aladjidi
Journal:  J Clin Immunol       Date:  2019-01-22       Impact factor: 8.317

Review 3.  CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency.

Authors:  Bernice Lo; Jill M Fritz; Helen C Su; Gulbu Uzel; Michael B Jordan; Michael J Lenardo
Journal:  Blood       Date:  2016-07-14       Impact factor: 22.113

Review 4.  Immunogenetics of gastrointestinal cancers: A systematic review and retrospective survey of inborn errors of immunity in humans.

Authors:  Beishi Zheng; Michael G Artin; Howard Chung; Bing Chen; Siming Sun; Benjamin L May; Chin Hur; Peter H R Green; Timothy C Wang; Jiheum Park; Xiao-Fei Kong
Journal:  J Gastroenterol Hepatol       Date:  2022-04-13       Impact factor: 4.369

5.  Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.

Authors:  Charlotte Schwab; Annemarie Gabrysch; Peter Olbrich; Virginia Patiño; Klaus Warnatz; Daniel Wolff; Akihiro Hoshino; Masao Kobayashi; Kohsuke Imai; Masatoshi Takagi; Ingunn Dybedal; Jamanda A Haddock; David M Sansom; Jose M Lucena; Maximilian Seidl; Annette Schmitt-Graeff; Veronika Reiser; Florian Emmerich; Natalie Frede; Alla Bulashevska; Ulrich Salzer; Desirée Schubert; Seiichi Hayakawa; Satoshi Okada; Maria Kanariou; Zeynep Yesim Kucuk; Hugo Chapdelaine; Lenka Petruzelkova; Zdenek Sumnik; Anna Sediva; Mary Slatter; Peter D Arkwright; Andrew Cant; Hanns-Martin Lorenz; Thomas Giese; Vassilios Lougaris; Alessandro Plebani; Christina Price; Kathleen E Sullivan; Michel Moutschen; Jiri Litzman; Tomas Freiberger; Frank L van de Veerdonk; Mike Recher; Michael H Albert; Fabian Hauck; Suranjith Seneviratne; Jana Pachlopnik Schmid; Antonios Kolios; Gary Unglik; Christian Klemann; Carsten Speckmann; Stephan Ehl; Alan Leichtner; Richard Blumberg; Andre Franke; Scott Snapper; Sebastian Zeissig; Charlotte Cunningham-Rundles; Lisa Giulino-Roth; Olivier Elemento; Gregor Dückers; Tim Niehues; Eva Fronkova; Veronika Kanderová; Craig D Platt; Janet Chou; Talal A Chatila; Raif Geha; Elizabeth McDermott; Su Bunn; Monika Kurzai; Ansgar Schulz; Laia Alsina; Ferran Casals; Angela Deyà-Martinez; Sophie Hambleton; Hirokazu Kanegane; Kjetil Taskén; Olaf Neth; Bodo Grimbacher
Journal:  J Allergy Clin Immunol       Date:  2018-05-04       Impact factor: 10.793

Review 6.  Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations.

Authors:  N Verma; S O Burns; L S K Walker; D M Sansom
Journal:  Clin Exp Immunol       Date:  2017-07-21       Impact factor: 4.330

Review 7.  Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development.

Authors:  Mohamed Abozeid; Antonio Rosato; Roberta Sommaggio
Journal:  Biomed Res Int       Date:  2017-07-11       Impact factor: 3.411

8.  Multifocal gastric adenocarcinoma in a patient with LRBA deficiency.

Authors:  Nina Bratanič; Jernej Kovač; Katka Pohar; Katarina Trebušak Podkrajšek; Alojz Ihan; Tadej Battelino; Magdalena Avbelj Stefanija
Journal:  Orphanet J Rare Dis       Date:  2017-07-18       Impact factor: 4.123

9.  Initiation of inflammatory tumorigenesis by CTLA4 insufficiency due to type 2 cytokines.

Authors:  Jason Miska; Jen Bon Lui; Kevin H Toomer; Priyadharshini Devarajan; Xiaodong Cai; JeanMarie Houghton; Diana M Lopez; Maria T Abreu; Gaofeng Wang; Zhibin Chen
Journal:  J Exp Med       Date:  2018-01-26       Impact factor: 14.307

10.  Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers.

Authors:  David Egg; Charlotte Schwab; Annemarie Gabrysch; Peter D Arkwright; Edmund Cheesman; Lisa Giulino-Roth; Olaf Neth; Scott Snapper; Satoshi Okada; Michel Moutschen; Philippe Delvenne; Ann-Christin Pecher; Daniel Wolff; Yae-Jean Kim; Suranjith Seneviratne; Kyoung-Mee Kim; Ji-Man Kang; Samar Ojaimi; Catriona McLean; Klaus Warnatz; Maximilian Seidl; Bodo Grimbacher
Journal:  Front Immunol       Date:  2018-09-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.